A small study published Monday found that the COVID-19 antiviral treatment Paxlovid may have use as a treatment for long COVID when administered outside of an infection. Administration of Paxlovid ...

Paxlovid use was associated with lower rates of hospitalization and death, particularly among older adults, a new study finds. The study published in PLOS Medicine on Jan. 17 found that Paxlovid ...

A large-scale study reveals azvudine’s comparable efficacy to Paxlovid, fewer adverse effects, and potential antitumor benefits in patients with liver cancer. Study: Real‐world effectiveness ...

The antiviral drug nirmatrelvir-ritonavir (Paxlovid) was linked to a lower risk of hospitalization within 30 days and major adverse cardiovascular events (MACEs) and death at 1 year in adults with ...

Prescribing guidelines and the benefits and risks of nirmatrelvir/ritonavir for COVID patients ...

A new real-world study published in PLOS Medicine that looked at outcomes of 703,647 patients with COVID-19 seen at 34 US clinics in 2022 and 2023 found that Paxlovid use was correlated with lower ...

It has now been over six months since the FDA authorized Paxlovid in December 2021 “for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older ...

US biotech Enanta Pharma has filed a lawsuit against Pfizer, claiming that its oral antiviral for COVID-19 Paxlovid infringes one of its patents and seeking damages from the pharma giant.

CEBU CITY — The provincial government of Cebu is now preparing to press civil and criminal charges against National Museum of the Philippines (NMP) director general Jeremy Barns for the museum's ...

5th Street Capital has unmatched expertise in the Non-QM space. We have solutions to the complex and varied ne... At Champions Funding, we Non-QM all day, every day! It’s our core business, and we ...